Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | NRAS |
Variant | G12C |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | NRAS G12C is a hotspot mutation that lies within a GTP-binding region of the Nras protein (UniProt.org). G12C has not been characterized, but can be predicted to confer a loss of function to the Nras protein based on the effects of HRAS G12C and KRAS G12C, which result in a loss of response to GTPase-activating proteins, and transformation of cultured cells (PMID: 26037647, PMID: 6092966). |
Associated Drug Resistance | |
Category Variants Paths |
NRAS mutant NRAS act mut NRAS G12C NRAS mutant NRAS exon2 NRAS G12X NRAS G12C |
Transcript | NM_002524.5 |
gDNA | chr1:g.114716127C>A |
cDNA | c.34G>T |
Protein | p.G12C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002524.5 | chr1:g.114716127C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_002524 | chr1:g.114716127C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
NM_002524.4 | chr1:g.114716127C>A | c.34G>T | p.G12C | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G12C | rectum cancer | predicted - sensitive | Panitumumab + Sotorasib | Case Reports/Case Series | Actionable | In a clinical case study, the combination of Lumakras (sotorasib) and Vectibix (panitumumab) resulted in a partial response after 12 weeks in a patient with metastatic rectal cancer harboring NRAS G12C (PMID: 37262393). | 37262393 |
NRAS G12C | Advanced Solid Tumor | sensitive | JDQ443 | Preclinical - Cell culture | Actionable | In a preclinical study, JDQ443 inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). | 38236605 |
NRAS G12C | Advanced Solid Tumor | sensitive | Sotorasib | Preclinical - Cell culture | Actionable | In a preclinical study, Lumakras (sotorasib) inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). | 38236605 |
NRAS G12C | colorectal cancer | predicted - sensitive | Panitumumab + Sotorasib | Case Reports/Case Series | Actionable | In clinical case study, treatment with the combination of Lumakras (sotorasib) and Vectibix (panitumumab) resulted in a decrease in the size of liver metastases and improved serum markers after 2 months of treatment in a patient with colorectal cancer harboring NRAS G12C (PMID: 38236605). | 38236605 |
NRAS G12C | Advanced Solid Tumor | sensitive | RM-018 | Preclinical - Cell culture | Actionable | In a preclinical study, RM-018 inhibited viability of cultured cells expressing NRAS G12C (PMID: 38236605). | 38236605 |
NRAS G12C | leukemia | predicted - sensitive | Sotorasib | Preclinical - Biochemical | Actionable | In a preclinical study, Lumakras (sotorasib) inhibited downstream signaling in leukemia cells harboring NRAS G12C in culture (PMID: 38236605). | 38236605 |